MIRA Pharmaceuticals, Inc. (MIRA)

MIRA Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing MIRA1a, a synthetic THC analog, for treating anxiety and cognitive decline associated with early-stage dementia. The company targets cannabinoid receptors to address anxiety and chronic pain.

46/100 AI Score MCap 62M Vol 96K

Company Overview

CEOErez Aminov
Employees2
HeadquartersBaltimore, MD, US
IPO Year2023

MIRA Pharmaceuticals offers a compelling investment opportunity in the biopharmaceutical sector, developing MIRA1a, a novel synthetic THC analog, targeting a significant unmet need in anxiety and cognitive decline associated with early-stage dementia, positioning them for substantial growth in the cannabinoid therapeutics market.

Investment Thesis

MIRA Pharmaceuticals presents a compelling investment opportunity due to its focused approach on developing MIRA1a, a synthetic THC analog, to address the growing market for anxiety and cognitive decline treatments. The company's strategy of targeting both CB1 and CB2 receptors offers a unique mechanism of action with the potential for improved efficacy and reduced side effects compared to existing treatments. The current market capitalization of $0.05 billion, coupled with a high beta of 1.82, suggests significant growth potential if MIRA1a achieves positive clinical trial results. Key value drivers include successful completion of clinical trials, strategic partnerships, and eventual commercialization of MIRA1a. Upcoming clinical trial milestones represent significant catalysts for stock appreciation. The absence of a dividend allows the company to reinvest earnings into research and development, further fueling growth.

Key Highlights

  • MIRA Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing MIRA1a.
  • MIRA1a is a synthetic THC analog targeting anxiety and cognitive decline associated with early-stage dementia.
  • The company targets cannabinoid type 1 and type 2 receptors to treat anxiety and chronic pain.
  • MIRA Pharmaceuticals has a market capitalization of $0.05 billion.
  • The company operates with a lean team of 2 employees, indicating a focus on efficient resource allocation.

Competitors

Strengths

  • Novel synthetic THC analog targeting a specific unmet need.
  • Dual-action mechanism targeting both CB1 and CB2 receptors.
  • Experienced management team.
  • Relatively low market capitalization, offering potential for high growth.

Weaknesses

  • Clinical-stage company with no currently approved products.
  • Limited financial resources.
  • High dependence on the success of MIRA1a.
  • Small team size.

Catalysts

  • Upcoming: Announcement of Phase I clinical trial results for MIRA1a (expected within the next 6-12 months).
  • Upcoming: Initiation of Phase II clinical trials for MIRA1a in patients with early-stage dementia (expected within the next 12-18 months).
  • Ongoing: Progress in securing strategic partnerships with pharmaceutical companies.
  • Ongoing: Expansion of the company's intellectual property portfolio through new patent filings.
  • Ongoing: Potential for securing orphan drug designation for MIRA1a.

Risks

  • Potential: Failure to obtain regulatory approval from the FDA for MIRA1a.
  • Potential: Unfavorable clinical trial results demonstrating lack of efficacy or safety concerns.
  • Potential: Competition from other companies developing similar treatments.
  • Ongoing: Dependence on securing additional funding to support clinical development activities.
  • Ongoing: Changes in the regulatory landscape regarding cannabinoid-based therapies.

Growth Opportunities

  • Advancement of MIRA1a through Clinical Trials: A primary growth opportunity lies in successfully navigating the clinical trial process for MIRA1a. Positive results from Phase I, II, and III trials will significantly increase the company's valuation and attract potential partnerships. The market for dementia and anxiety treatments is projected to reach billions of dollars by 2030, offering a substantial revenue opportunity if MIRA1a proves effective and safe. Timeline: Ongoing clinical trials with data readouts expected in the next 12-24 months.
  • Strategic Partnerships and Licensing Agreements: MIRA Pharmaceuticals can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of MIRA1a. Licensing agreements can provide upfront payments, milestone payments, and royalties, generating significant revenue streams. The global pharmaceutical licensing market is estimated to be worth hundreds of billions of dollars annually. Timeline: Potential partnerships can be established within the next 12-18 months following positive clinical trial data.
  • Expansion of Pipeline with New Cannabinoid Analogs: MIRA can leverage its expertise in synthetic cannabinoid development to expand its pipeline with new drug candidates targeting other neurological and pain-related disorders. This diversification will reduce the company's reliance on MIRA1a and create additional growth opportunities. The market for pain management drugs is substantial and growing, driven by an aging population and increasing prevalence of chronic pain conditions. Timeline: New drug candidates can be identified and developed within the next 2-3 years.
  • Securing Orphan Drug Designation: Pursuing orphan drug designation for MIRA1a in specific rare dementia subtypes can provide significant regulatory and financial benefits, including market exclusivity and tax credits. This strategy can enhance the commercial attractiveness of MIRA1a and accelerate its adoption by healthcare providers. The orphan drug market is a rapidly growing segment of the pharmaceutical industry. Timeline: Orphan drug designation can be pursued within the next 6-12 months based on clinical data and regulatory guidelines.
  • Geographic Expansion into International Markets: MIRA Pharmaceuticals can expand its market reach by seeking regulatory approval for MIRA1a in international markets, such as Europe and Asia. This will significantly increase the company's potential customer base and revenue opportunities. The global market for dementia and anxiety treatments is substantial, with significant growth potential in emerging markets. Timeline: International expansion can be pursued within the next 3-5 years following successful commercialization in the United States.

Opportunities

  • Positive clinical trial results for MIRA1a.
  • Strategic partnerships with larger pharmaceutical companies.
  • Expansion of pipeline with new cannabinoid analogs.
  • Securing orphan drug designation for specific dementia subtypes.

Threats

  • Failure to obtain regulatory approval for MIRA1a.
  • Competition from other companies developing similar treatments.
  • Changes in regulatory landscape regarding cannabinoid-based therapies.
  • Unfavorable clinical trial results.

Competitive Advantages

  • Proprietary synthetic cannabinoid analogs with patent protection.
  • Targeting a specific unmet need in anxiety and cognitive decline associated with early-stage dementia.
  • Dual-action approach targeting both CB1 and CB2 receptors.
  • Experienced management team with expertise in drug development and commercialization.

About

MIRA Pharmaceuticals, Inc., incorporated in 2020 and headquartered in Baltimore, Maryland, is a clinical development stage biopharmaceutical company dedicated to addressing critical unmet needs in neurological disorders. The company's primary focus is the development and commercialization of MIRA1a, a novel synthetic tetrahydrocannabinol (THC) analog. This innovative compound is under investigation for the treatment of adult patients suffering from anxiety and cognitive decline, conditions frequently associated with the early stages of dementia. MIRA1a is designed to target both cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors, offering a dual-action approach to alleviate anxiety and manage chronic pain. Formerly known as MIRA1a Therapeutics, Inc., the company is committed to rigorous clinical trials and regulatory processes to bring this potential therapeutic to market. MIRA's strategic focus on synthetic cannabinoids allows for precise control over dosage and formulation, potentially overcoming some of the challenges associated with naturally derived cannabis products. With a lean operational structure and a clear clinical pathway, MIRA Pharmaceuticals aims to establish itself as a key player in the emerging field of cannabinoid-based pharmaceuticals.

What They Do

  • Develops synthetic tetrahydrocannabinol (THC) analogs.
  • Focuses on treatments for anxiety and cognitive decline.
  • Targets cannabinoid type 1 (CB1) and type 2 (CB2) receptors.
  • Conducts clinical trials to evaluate the safety and efficacy of MIRA1a.
  • Aims to commercialize MIRA1a for the treatment of adult patients with early-stage dementia.
  • Researches and develops new cannabinoid-based therapies.

Business Model

  • Develop and patent novel synthetic cannabinoid analogs.
  • Conduct preclinical and clinical trials to demonstrate safety and efficacy.
  • Seek regulatory approval from the FDA for commercialization.
  • Partner with pharmaceutical companies for manufacturing and distribution, or establish in-house capabilities.

Industry Context

MIRA Pharmaceuticals operates within the drug manufacturers industry, a segment of the broader healthcare sector. The market for anxiety and cognitive decline treatments is substantial and growing, driven by an aging population and increasing awareness of mental health issues. The competitive landscape includes both traditional pharmaceutical companies and emerging biotech firms focused on cannabinoid-based therapies. MIRA's focus on synthetic cannabinoids offers a potential advantage in terms of consistency and regulatory compliance. The industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition.

Key Customers

  • Adult patients suffering from anxiety and cognitive decline associated with early-stage dementia.
  • Healthcare providers, including physicians and psychiatrists, who prescribe treatments for these conditions.
  • Pharmacies and hospitals that dispense and administer the medication.
  • Potential pharmaceutical partners seeking to license or acquire MIRA1a.
AI Confidence: 70% Updated: 2/3/2026

Financials

Chart & Info

Price Chart

MIRA Pharmaceuticals, Inc. (MIRA) stock price: $1.49 (+0.00, +0.00%)

Why Bull

  • •Recent insider buying signals confidence in MIRA's future, suggesting that executives believe in the company's growth potential.
  • •Community sentiment has shifted positively, with discussions highlighting MIRA's innovative pipeline and potential breakthroughs in pharmaceuticals.
  • •Analysts are increasingly optimistic about MIRA's prospects, citing favorable regulatory developments that may expedite product approvals.
  • •The recent partnerships with research institutions have generated buzz, enhancing MIRA's credibility and visibility in the market.

Why Bear

  • •Concerns over the competitive landscape in the pharmaceutical sector have emerged, as rivals are also advancing similar drug candidates.
  • •Some community members express skepticism about MIRA's ability to deliver on its promises, pointing to past delays in product launches.
  • •Market perception has been tempered by broader economic uncertainties affecting the healthcare sector, leading to cautious investor sentiment.
  • •Recent negative news regarding supply chain issues has raised alarms about MIRA's operational efficiency and ability to meet demand.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
95,841

Rationale

AI-generated technical analysis for MIRA including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss MIRA Pharmaceuticals, Inc. (MIRA) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for MIRA.

Make a Prediction

Set your price target for MIRA Pharmaceuticals, Inc. (MIRA), choose a timeframe, and track your prediction accuracy.

Current price: $1.49

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MIRA.

Price Targets

Wall Street price target analysis for MIRA.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

45.5/100

Score Factors

  • Revenue Growth 5/100

    Revenue growth data is currently unavailable for this company.

  • Gross Margin 5/100

    Gross margin data is currently unavailable for this company.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates MIRA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does MIRA Pharmaceuticals, Inc. do?

MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of MIRA1a, a synthetic tetrahydrocannabinol (THC) analog. Their primary focus is to address the unmet medical needs of patients suffering from anxiety and cognitive decline typically associated with early-stage dementia. MIRA1a is designed to target both cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors, offering a potential therapeutic approach for anxiety and chronic pain management. The company is currently conducting clinical trials to evaluate the safety and efficacy of MIRA1a.

Is MIRA stock a good buy?

MIRA Pharmaceuticals presents a speculative investment opportunity, characterized by high risk and potentially high reward. The company's success hinges on the successful development and commercialization of MIRA1a. While the market for anxiety and cognitive decline treatments is substantial, MIRA faces significant competition and regulatory hurdles. The current P/E ratio of -0.82 reflects the company's lack of profitability. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in MIRA stock. Positive clinical trial results and strategic partnerships could significantly increase the stock's value.

What are the main risks for MIRA?

The primary risks for MIRA Pharmaceuticals include the inherent uncertainties associated with clinical-stage drug development. Failure to obtain regulatory approval from the FDA for MIRA1a would be a significant setback. Unfavorable clinical trial results, demonstrating a lack of efficacy or safety concerns, could also negatively impact the company's prospects. Competition from other companies developing similar treatments poses another risk. Additionally, MIRA's dependence on securing additional funding to support its clinical development activities and potential changes in the regulatory landscape regarding cannabinoid-based therapies represent ongoing challenges.

Is MIRA a good stock to buy?

Whether MIRA is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the MIRA MoonshotScore?

The MoonshotScore for MIRA is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is MIRA data updated?

MIRA stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to MIRA is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for MIRA?

Growth catalysts for MIRA Pharmaceuticals, Inc. (MIRA) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes MIRA Pharmaceuticals, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are MIRA's main competitors?

MIRA Pharmaceuticals, Inc. (MIRA) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether MIRA has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about MIRA?

Wall Street analyst coverage for MIRA includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is MIRA's market cap?

Market capitalization (market cap) for MIRA is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows MIRA's current market cap alongside enterprise value and other valuation metrics.

How has MIRA stock performed recently?

MIRA's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing MIRA's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in MIRA?

Key risk categories for MIRA include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures MIRA's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling MIRA?

Insider trading activity for MIRA tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is MIRA a good stock for beginners?

MIRA Pharmaceuticals, Inc. (MIRA) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is MIRA for first-time investors?

Every stock carries risk, including MIRA Pharmaceuticals, Inc. (MIRA). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like MIRA.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Information is based on publicly available sources and may be subject to change.
  • Investment in clinical-stage biopharmaceutical companies is highly speculative and involves significant risks.
Data Sources
profilefundamentalsexistingCopy